Takeda

We follow the science, to unlock innovation and pursue sustainable answers. We are guided by our commitment to patients, our people and the planet. Our vision is to deliver life-transforming treatments to those in need. We are steadfast in our purpose for better health for people and a brighter future for the world.

Pharmaceutical science is more than just developing therapies—it’s about transforming lives. Plasma-derived therapies are a lifeline for people with rare conditions, and advancing plasma fractionation will help make these therapies more accessible and sustainable. Andreas Liebminger, head of pharmaceutical science within our research and development organization, shares his insights on sustainable plasma science. With over 23 years in the industry, he highlights how emerging technologies can revolutionize plasma fractionation, improve efficiency, and reduce environmental impact. #PlasmaTherapies #Innovation #Sustainability

We have a vision for the future where health care is more accessible, inclusive, sustainable and affordable for all, and we believe our people are our greatest promise for delivering it. This #WorldHealthDay, we want to take a moment to recognize #TeamTakeda’s efforts to deliver on our commitments to create better health for people and a brighter future for the world. Thank you to all our employees who work so hard to #MakeHistoryChangeFutures

30 years and counting! That’s how long we’ve pushed boundaries in science and medicine to address the very real needs of the #Alpha1 community, and we won’t stop. Earlier this month, we joined the Alpha-1 Foundation, patients, health care professionals and others in Lisbon to support driving awareness about alpha-1 antitrypsin deficiency (AATD) liver disease, the importance of early detection and opportunities to advance medical research in the space. Listening firsthand to the experiences of patients living with this often silent and devastating disease inspires us to continue our work with greater purpose and urgency. #AATD #liverdisease

Takeda Danmark deltager i ’Et Sundt Match’ 2025 på Aalborg Universitet. Hos Takeda forstår vi vigtigheden af at støtte studerende i overgangen fra studielivet til rollen som unge professionelle på arbejdsmarkedet. Derfor engagerer vi os i karriereinitiativer og arrangementer landet over, og torsdag den 10. april besøger vi Aalborg Universitet. Her vil vores kollegaer Petra (Data, Digital & Technology) og Jeanett (Patient Value, Access & External Affairs) dele deres erfaringer og give et indblik i, hvad det vil sige at arbejde hos Takeda og generelt i life science-industrien. Læs mere om arrangementet her: https://lnkd.in/ee3Dvsss #TakedaDenmark C-ANPROM/DK/NON/0022

In this video, Kevin shares his journey being diagnosed and living with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disease that includes symptoms such as muscle weakness, difficulty with balance, and loss of mobility. Living with #CIDP has given Kevin a new perspective on life – one in which he focuses on finding the joy in each day.

Our employees’ job search journeys may look different, but they all have one thing in common: their decision to bring their talents to Takeda. We asked new team members what influenced their decision to join us—discover the highlights from their candidate experiences: https://bit.ly/3RzkFLu #MakeHistoryChangeFutures #TeamTakeda

We’ve partnered with the Kyoto City Zoo to educate the next generation on environmental conservation. Together with city residents, we cultivated medicinal herbs and grew food for the zoo animals using natural compost. Discover more about our efforts to make a positive impact on the environment and education: https://lnkd.in/ece_KvdS #Kyoto #garden #zoo #OurStories

We’re looking forward to connecting with neurologists and neuroscience professionals at the American Academy of Neurology (AAN) 2025 Annual Meeting (#AANAM). Rare sleep-wake disorders like #narcolepsy are serious neurological conditions that are often underrecognized. The data we will present include real-world patient journey insights and novel patient-reported outcome measures. We are focused on this area of study to help support diagnostic and disease management strategies that capture the scope of living with narcolepsy. We will also share data from our narcolepsy type 1 orexin agonist investigative clinical trial. If you’re a healthcare professional planning to attend, be sure to visit us at booth #1046. We hope to see you there. In the meantime, you can learn more about Takeda’s neuroscience efforts here: https://lnkd.in/etcgUJsP

We are proud to partner with Innovative Health Initiative (IHI) on the INTERCEPT project, Europe’s first-ever prevention and disease interception trial focused on #CrohnsDisease (CD). Together, we’re aiming to change the future of CD by utilizing blood-based biomarkers to intercept the disease in high-risk individuals before symptoms develop. Hear about INTERCEPT from Marcelo Freire, Vice President and Global Medical Affairs Head, Gastroenterology.